Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

The use of peginterferon in monotherapy or in combination with ribavirin for the treatment of acute hepatitis C.

Nunnari G, Montineri A, Portelli V, Savalli F, Fatuzzo F, Cacopardo B.

Eur Rev Med Pharmacol Sci. 2012 Aug;16(8):1013-6.

PMID:
22913149
2.

Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.

Tseng PL, Chen TC, Chien YS, Hung CH, Yen YH, Chang KC, Tsai MC, Lin MT, Lee CT, Shen CH, Hu TH.

Am J Kidney Dis. 2013 Oct;62(4):789-95. doi: 10.1053/j.ajkd.2013.03.037. Epub 2013 Jun 5.

PMID:
23746377
3.

OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients.

Carosi G, Bruno R, Cariti G, Nasta P, Gulminetti R, Galli M, Angarano G, Verucchi G, Pontali E, Capetti A, Raise E, Ravasio V, Maida I, Iannacone C, Caputo A, Puoti M.

Antivir Ther. 2014;19(8):735-45. doi: 10.3851/IMP2757. Epub 2014 Feb 28.

PMID:
24583976
4.

Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.

Bonardi R, Tabone M, Manca A, Pellicano R, Ciancio A, Rizzetto M.

Biomed Pharmacother. 2011 Jul;65(4):303-6. doi: 10.1016/j.biopha.2011.03.004. Epub 2011 May 30.

PMID:
21723079
5.

Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.

Marcellin P, Cooper C, Balart L, Larrey D, Box T, Yoshida E, Lawitz E, Buggisch P, Ferenci P, Weltman M, Labriola-Tompkins E, Le Pogam S, Nájera I, Thomas D, Hooper G, Shulman NS, Zhang Y, Navarro MT, Lim CY, Brunda M, Terrault NA, Yetzer ES.

Gastroenterology. 2013 Oct;145(4):790-800.e3. doi: 10.1053/j.gastro.2013.06.051. Epub 2013 Jun 26.

PMID:
23811112
6.

Hepatitis C virus genotype 5: prospective evaluation of peginterferon/ribavirin treatment efficacy and predictive value of on-treatment virological responses for sustained virological response.

Papastergiou V, Skorda L, Lisgos P, Stampori M, Ntetskas G, Papakonstantinou L, Prodromidou K, Karatapanis S.

J Clin Gastroenterol. 2014 Feb;48(2):160-5. doi: 10.1097/MCG.0b013e3182a1789c.

PMID:
24100748
7.

Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.

Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, Hsu CS, Tseng TC, Wang CC, Lai MY, Chen JH, Chen PJ, Chen DS, Kao JH.

Clin Infect Dis. 2008 Nov 15;47(10):1260-9. doi: 10.1086/592579.

PMID:
18834319
8.
9.

Treatment of hepatitis C virus carriers with persistently normal alanine aminotransferase levels with peginterferon alpha-2a and ribavirin: a multicentric study.

Puoti C, Pellicelli AM, Romano M, Mecenate F, Guarisco R, Barbarini G, Mazzoni E, Spilabotti L, Bellis L, Paglia F, Barlattani A, Picardi A, Paffetti A, Bonaventura ME, Nosotti L, Mitidieri O, Dell'Unto O, Villani R, Dell'Unto C, Morrone A, Soccorsi F; Club Epatologico Ospedaliero (Hospital Liver Club - CLEO).

Liver Int. 2009 Nov;29(10):1479-84. doi: 10.1111/j.1478-3231.2009.02042.x. Epub 2009 Apr 28.

PMID:
19422478
10.

Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C.

Sagnelli E, Pisaturo M, Stanzione M, Messina V, Alessio L, Sagnelli C, Starace M, Pasquale G, Coppola N.

Clin Gastroenterol Hepatol. 2013 Sep;11(9):1174-1180.e11. doi: 10.1016/j.cgh.2013.03.025. Epub 2013 Apr 13.

PMID:
23591280
11.

Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.

Katz LH, Goldvaser H, Gafter-Gvili A, Tur-Kaspa R.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD008516. doi: 10.1002/14651858.CD008516.pub2. Review.

PMID:
22972122
12.

Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort.

Vogel M, Dominguez S, Bhagani S, Azwa A, Page E, Guiguet M, Valantin MA, Katlama C, Rockstroh JK, Nelson M.

Antivir Ther. 2010;15(2):267-79. doi: 10.3851/IMP1501.

PMID:
20386082
13.

Pegylated interferon-α monotherapy leads to low response rates in HIV-infected patients with acute hepatitis C.

Arends JE, van Assen S, Stek CJ, Wensing AM, Fransen JH, Schellens IM, Spijkers SN, Mudrikova T, van Baarle D, Sprenger HG, Hoepelman AI.

Antivir Ther. 2011;16(7):979-88. doi: 10.3851/IMP1843.

PMID:
22024513
14.

[Epidemic outbreak of acute hepatitis C--clinical course, histology and effectiveness of therapy].

Cianciara J, Jabłońska J, Horban A, Walewska-Zielecka B.

Przegl Epidemiol. 2005;59(2):385-94. Polish.

PMID:
16190545
15.

Rapid normalization of alanine aminotransferase predicts viral response during combined peginterferon and ribavirin treatment in chronic hepatitis C patients.

Kim YJ, Jang BK, Kim ES, Park KS, Cho KB, Chung WJ, Hwang JS.

Korean J Hepatol. 2012 Mar;18(1):41-7. doi: 10.3350/kjhep.2012.18.1.41. Epub 2012 Mar 22.

16.

Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.

Watanabe S, Kobayashi Y, Kawata K, Noritake H, Chida T, Nagasawa M, Kageyama F, Kawamura K, Sasada Y, Suda T.

Intern Med. 2015;54(3):273-9. doi: 10.2169/internalmedicine.54.2718.

17.

Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.

Galán RJ, Cidoncha EC, Martin MF, Rodriguez CC, Almeida CV, Verdugo RM.

J Manag Care Pharm. 2013 Jul-Aug;19(6):448-53.

18.

Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C.

Christensen PB, Krarup HB, Laursen AL, Madsen PH, Pedersen C, Schlichting P, Orholm M, Ring-Larsen H, Bukh J, Krogsgaard K.

Scand J Gastroenterol. 2012 Sep;47(8-9):1115-9. doi: 10.3109/00365521.2012.694905. Epub 2012 Jun 7.

PMID:
22670704
19.

Acute hepatitis C: a 24-week course of pegylated interferon α-2b versus a 12-week course of pegylated interferon α-2b alone or with ribavirin.

Santantonio T, Fasano M, Sagnelli E, Tundo P, Babudieri S, Fabris P, Toti M, Di Perri G, Marino N, Pizzigallo E, Angarano G; Acute Hepatitis C Study Group.

Hepatology. 2014 Jun;59(6):2101-9. doi: 10.1002/hep.26991. Epub 2014 Apr 29.

PMID:
24442928
20.

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, Rivero A, Mak C, Thompson S, Howe AY, Wenning L, Sklar P, Wahl J, Greaves W; P05411 study investigators.

Lancet Infect Dis. 2013 Jul;13(7):597-605. doi: 10.1016/S1473-3099(13)70149-X. Epub 2013 Jun 12.

PMID:
23768747

Supplemental Content

Support Center